体外診断薬（IVD）の動向と市場最新情報：2024年12月

体外診断用医薬品（IVD）市場は、技術の進歩と機会の拡大に牽引され、力強い成長を示しています。診断検査は、単に病気を診断するものから、精密医療治療のための重要な知見を提供するものへと進化しています。COVID-19検査は減少しましたが、2024年の全体収益への貢献は続いています。市場は引き続きダイナミックで、新製品の開拓、世界の医療支出のシフト、規制の変更、疾病動向の影響を受け、回復力を維持しています。

体外診断用医薬品（IVD）市場には、著しい成長を遂げ、業界の注目を集めている分野がいくつかあります。POC（ポイント・オブ・ケア）検査、がん診断薬、コンパニオン診断薬、免疫化学、質量分析などです。さらに、核酸アッセイ、遺伝子検査、HPV分子診断も大きな成長を遂げようとしており、今後の重要な注目分野となっています。

診断検査は今やヘルスケアの要であり、診断と治療決定の両面で役立っています。COVID-19検査の減少にもかかわらず、中核的な診断分野は一貫した成長を示しています。市場の進化は、革新的な製品、世界の医療費の動向、規制の変化、新たな疾病動向などの要因によってもたらされます。

主な成長分野には、次世代シーケンシング（NGS）、個別化医療、質量分析などがあります。免疫化学、POC検査、分子診断もIVDの将来において重要な役割を果たすと予想されます。同市場は継続的な革新と適応を特徴としています。

当レポートでは、体外診断薬（IVD）の動向と市場最新情報について調査し、2024年の市場動向と成長促進要因、今後の見通しなどの最新の洞察を提供しています。

目次

第1章 世界のIVD市場-2024年12月更新

• IVD市場の需要と成長
• COVID-19診断市場
• COVID-19が市場セグメントに与える影響

第2章 製品の動向と新開発

• 厳選された新製品-2024年第3四半期- コアIVD製品の発売、開発、動向
• フローサイトメトリ
• 免疫測定
• 分子
• パーソナライズ医療
• 有価証券
• シーケンシング
• COVID-19の主要動向-2024年第3四半期
• 抗原/抗体
• 分子

第3章 IVD市場のトップ参加者の結果

• 厳選された競争リーダーの最新情報
• 第3四半期のM&A活動
• Abbott Laboratories
• Becton Dickinson and Co
• bioMerieux SA
• Danaher Corporation
• Dexcom, Inc.
• Exact Sciences
• Roche Diagnostic
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific

第4章 新たな機会

• 液体生検におけるAI
• 抗菌薬耐性
• 単一分子分析装置
• 脂質パネルに関する新しいガイドライン
• 遠隔医療

The in vitro diagnostics (IVD) market has demonstrated robust growth, driven by technological advancements and expanding opportunities. Diagnostic testing has evolved from merely diagnosing illnesses to providing critical insights for precision medicine treatments. Although COVID-19 testing has declined, it continues to contribute to overall revenues in 2024. The market remains dynamic, influenced by new product developments, shifts in global health spending, regulatory changes, and disease trends, maintaining its resilience.

Several segments within the IVD market are experiencing significant growth and attracting industry attention. These include Point-of-Care (POC) testing, cancer diagnostics, companion diagnostics, immunochemistry, and mass spectrometry. Additionally, nucleic acid assays, gene testing, and HPV molecular diagnostics are poised for substantial growth, marking them as key areas of interest for the future.

Diagnostic testing is now a cornerstone of healthcare, aiding in both diagnosis and treatment decisions. Despite the decline in COVID-19 testing, core diagnostic segments have shown consistent growth. The market's evolution is driven by factors such as innovative products, global health expenditure changes, regulatory shifts, and emerging disease trends.

Key growth areas include next-generation sequencing (NGS), personalized medicine, and mass spectrometry. Immunochemistry, POC testing, and molecular diagnostics are also expected to play crucial roles in the future of IVD. The market is characterized by continuous innovation and adaptation.

The report, "In Vitro Diagnostic (IVD) Trends and Market Update: December 2024" by Kalorama Information provides the latest insights into these trends and other factors shaping the market.

It covers:

• Drivers of growth in the IVD market in 2024
• Major trends impacting the market in 2024
• Product trends and new developments shaping the IVD market in 2024

Highlighted trends from Q3 2023 to Q3 2024 include:

• The increasing role of AI technologies in IVD development and testing
• Exponential growth in the POC diabetes market
• Double-digit growth in HPV molecular testing
• Significant growth in blood banking molecular NAT screening due to advancements in nucleic acid method

Table of Contents

Chapter 1: Worldwide IVD Market - December 2024 Update

• IVD Market Demand and Growth
  • Figure 1-1: Q1 2024 - Q3 2024 Segment Performance Commentary
  • Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) (Clinical Chemistry; Immunoassays - non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology - Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
  • Figure 1-2: IVD Segment Performance, Q1 2024 - Q4 2024 estimated ($ million) (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other)
  • Figure 1-3: IVD Segment Performance, Total Market Value, 2024 estimated ($ million) (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other)
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales, by Segment, 2024 ($ million) (Immunoassay [Antigen and Serology], Molecular, Rapid [POC Professional and POC At-Home])
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market excluding and with COVID-19, 2024 ($ million)
  • Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) (IVD Market excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments)
  • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, Q1 2024 - Q4 2024 estimated ($ million)
  • Table 1-4: Global In Vitro Diagnostic Market - YoY Growth, 2023-2024 (%) (Clinical Chemistry; Immunoassays - non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology - Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
  • Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth, 2023-2024 (%) (Clinical Chemistry; Immunoassays - non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology - Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)

Chapter 2: Product Trends and New Developments

• Selected New - Q3 2024 - Core IVD Product Launches, Developments and Trends
• Flow Cytometry
• Immunoassay
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Selected COVID-19 Developments - Q3 2024
  • Figure 2-1: COVID-19 Test Market, by Type, Q1 2024 - Q4 2024 estimated ($ million) (Antigen, Molecular, Rapid, Serology)
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth, by Leading Competitors, Change in Sales, 2023-2024 (%) (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific)
  • Figure 3-2: Top 10 IVD Companies: Changes in Market Distribution for IVD Sales, 2021-2024 estimated - Roche and Abbott Battle for #1 Spot (%) (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific)
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
• Q3 M&A Activity
  • Table 3-1: Q3 2024 Merger and Acquisition Activity
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
• bioMerieux SA
  • Table 3-4: bioMerieux Corporate Summary
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
• Dexcom, Inc.
  • Table 3-6: Dexcom Corporate Summary
• Exact Sciences
  • Table 3-7: Exact Sciences Corporate Summary
• Roche Diagnostic
  • Table 3-8: Roche Diagnostic Corporate Summary
• Siemens Healthineers
  • Table 3-9: Siemens Healthineers Corporate Summary
• Sysmex Corporation
  • Table 3-10: Sysmex Corporate Summary
• Thermo Fisher Scientific
  • Table 3-11: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

• AI in Liquid Biopsy
  • Table 4-1: Selected AI/Liquid Biopsy Initiatives
• Antimicrobial Resistance
• Single Molecule Analyzer
• New Guidance for Lipid Panels
• Telehealth